• Regulatory NewsRegulatory News

    COVID test EUAs updated with pooled serial testing option

    The US Food and Drug Administration (FDA) has taken steps to make it easier to pool test samples for many molecular diagnostic tests for SAR-CoV-2, the virus that causes COVID-19.   The agency’s amendment to many test emergency use authorizations (EUAs) now allows sample pooling to screen asymptomatic individuals when the testing is performed at least once weekly as part of a screening strategy.   “Pooling, the process of combining multiple specimens together to mo...
  • Regulatory NewsRegulatory News

    FDA finds mess of sterility problems at Emergent

    Officials from the US Food and Drug Administration (FDA) urged Emergent BioSolutions to stop producing vaccines until it corrects a litany of unsafe practices at the plant which compromised the quality of products. These problems were identified following a recent inspection of the plant’s facility in Baltimore.   The company was contracted by Johnson & Johnson to manufacture its COVID-19 vaccine but had to throw out 15 million doses recently due to a mix-up of ingredi...
  • ReconRecon

    Recon: Vertex inks $900M deal with CRISPR Therapeutics; Congress investigates Emergent's contracts

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US Is the US FDA at A Tipping Point? ( Pink Sheet ) New report finds COVID-19 pandemic causes dramatic shifts in prescription drug spending ( EurekAlert ) Trump administration awarded a firm $1.3 billion to make Covid vaccine syringes. Where are they? ( NBC ) U.S. Reaches Another Crucial Juncture In The Fight Against COVID-19 ( NPR ) Biden to push for more vacci...
  • RoundupsRoundups

    FDA Approvals Roundup: Nextstellis, Ragwitek, Opdivo

    A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA).   New approvals Nextstellis cleared as first new oral contraceptive in over 50 years Mayne’s Nextstellis (drospirenone and estetrol [E4] tablet) has been approved for the prevention of pregnancy in individuals of reproductive potential.   Nextstellis was approved based on efficacy findings from the year-long phase 3, prospective, multicenter, open-label, s...
  • Regulatory NewsRegulatory News

    EU clinical trial portal and database declared functional

    The European Medicines Agency (EMA) announced that its long-delayed EU clinical trial portal and database are fully functional, paving the way for the launch of the EU Clinical Trial Information System (CTIS) and the application of the EU Clinical Trial Regulation early next year.   The CTIS was originally expected in September 2018; however, a series of delays have pushed back the launch date for the system, and the EU Clinical Trial Regulation it is intended to suppo...
  • Regulatory NewsRegulatory News

    MDUFA V: Deficiency letters, staffing and funding emerge as issues in early negotiations

    After a delayed start, the US Food and Drug Administration (FDA) released minutes from the first two meetings held with the medical device industry to negotiation the terms of the next Medical Device User Fee Amendments (MDUFA V) program.   FDA and industry had originally planned to kick off the MDUFA V negotiations with a public meeting last April, but the meeting was delayed by six months due to COVID-19. (RELATED: MDUFA V: Industry wants fine tuning while FDA se...
  • Regulatory NewsRegulatory News

    EMA: J&J vaccine possibly linked to rare clots; benefit outweighs risk

    After a review by its safety committee, the European Medicines Agency (EMA) has concluded that a “possible link” exists between receipt of the COVID-19 vaccine from Janssen, the pharmaceutical division of Johnson & Johnson, and a rare combination of blood clots in large veins and low platelet counts.   In a press release and briefing, PRAC, EMA’s safety committee, announced that it judged that the overall benefit-risk profile for the vaccine remains positive but conclu...
  • RoundupsRoundups

    Asia-Pacific Roundup: TGA investigating death linked to AstraZeneca vaccine

    Australia’s Therapeutic Goods Administration (TGA)’s Vaccine Safety Investigation Group (VSIG) announced that a 48-year-old woman who was vaccinated in New South Wales and admitted to the hospital died four days after receiving the vaccine.   The patient died of thrombosis with thrombocytopenia syndrome (TTS), or blood clots in the arteries and veins, that may be linked to the AstraZeneca vaccine. Officials says this is the third Australian report of a case of TTS foll...
  • ReconRecon

    Recon: Abbott profits triple with OTC test launch; Good news for bluebird

      Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US Large clinical trial to study repurposed drugs to treat COVID-19 symptoms ( NIH ) Q&A with Acting FDA Commissioner Janet Woodcock on the Future of the FDA ( BioSpace ) Covid cases, vaccinations remain elevated as U.S. nears Biden’s 200 million goal ( CNBC ) U.S. CDC expands COVID-19 vaccine eligibility to 16 and older ( Reuters ) Johnson & Johnson reports...
  • Regulatory NewsRegulatory News

    ICH shares "work-in-progress" update to GCP guidance

    The International Conference on Harmonization (ICH) has made available a draft version of its updated principles for good clinical practice. The principles are to be considered a “work-in-progress,” wrote ICH in announcing the availability of the updates, which are still in development by the ICH’s E6(R3) expert working group.   “The principles are interdependent and should be considered in their totality to assure ethical trial conduct, participant safety, and reliabl...
  • Regulatory NewsRegulatory News

    GDUFA III: Use MDUFA model to create competition in generic drug markets

    As negotiations for the reauthorization of the Generic Drug User Fee Act (GDUFA) continue, stakeholders should consider a new financial model to improve equity and competition in generic drug markets, according to a recent Health Affairs blog post.   GDUFA was enacted in 2012 and reauthorized in 2017 as GDUFA II with the goal to “supplement FDA funds to expedite generic drug approval and inject competition in generic drug markets,” Margaret M. Dotzel, attorney and fo...
  • Regulatory NewsRegulatory News

    FDA issues final rule removing certain software from medical device regulations

    The US Food and Drug Administration (FDA) has issued a final rulemaking that eliminates certain software intended to transfer, store or display clinical laboratory tests from being regulated as medical devices.   This action was taken to conform to the medical software provisions of the 21 st Century Cures Act , enacted on 13 December 2016. The law amended the definition of a device in the Federal Food, Drug, and Cosmetic Act (FD&C Act) to exclude such software; th...